Hypothesis

Administering a mechanistically validated probiotic‑prebiotic pair during the host’s active phase (when gut permeability and vagal afferent sensitivity are naturally elevated) will significantly increase colonic short‑chain fatty acid (SCFA) production, reduce systemic inflammation, and improve anxiety/depression scores compared with the same intervention given during the rest phase.

Rationale

• The gut‑brain axis operates via vagal signaling, immune mediators, and microbial metabolites【https://pmc.ncbi.nlm.nih.gov/articles/PMC12883760/】.
• Over 90% of serotonin is gut‑derived, and dysbiosis‑induced “leaky gut” permits pro‑inflammatory molecules to cross the blood‑brain barrier【https://pmc.ncbi.nlm.nih.gov/articles/PMC12366197/】.
• Human trials show strain‑specific probiotic effects and null prebiotic results, suggesting missing contextual factors【https://pmc.ncbi.nlm.nih.gov/articles/PMC12314587/】.
• Intestinal epithelial tight‑junction proteins and enterochromaffin cell activity are under circadian control, peaking in the active phase of the host【https://pubmed.ncbi.nlm.nih.gov/30643162/】.
• Vagal afferent firing rates also exhibit diurnal variation, with higher sensitivity during wakefulness【https://pubmed.ncbi.nlm.nih.gov/31182275/】.
• Therefore, delivering probiotics and prebiotics when the gut barrier is more permissive and vagal tone is primed should maximize metabolite‑driven signaling and anti‑inflammatory effects.

Predictions

1. Metabolite output – Fecal acetate, propionate, and butyrate concentrations will be ≥20 % higher after active‑phase dosing versus rest‑phase dosing.
2. Immune read‑outs – Plasma IL‑6 and TNF‑α will decrease by ≥15 % only in the active‑phase group.
3. Neural read‑out – Heart‑rate variability (HF‑HRV), a proxy for vagal tone, will show a greater increase (>5 % RMSSD) in the active‑phase condition.
4. Clinical outcome – Anxiety (GAD‑7) and depression (PHQ‑9) scores will improve by ≥3 points in the active‑phase group but not in the rest‑phase group.

Experimental Design (testable & falsifiable)

• Design: Double‑blind, placebo‑controlled, crossover trial in 60 adults with mild‑to‑moderate anxiety/depression.
• Arms: (A) Lactobacillus plantarum PS128 + galactooligosaccharide (GOS) given at ZT4 (active phase); (B) same supplement at ZT16 (rest phase); (C) placebo at each time point.
• Washout: 2 weeks between periods.
• Measurements: Fecal SCFAs (GC‑MS), serum cytokines (ELISA), HF‑HRV (5‑min ECG), GAD‑7/PHQ‑9 at baseline and 2 weeks post‑each period.
• Statistical test: Mixed‑effects model with fixed effects for timing, treatment, and period; interaction term (timing × treatment) is the primary hypothesis test.

Falsifiability

If the interaction term is non‑significant (p > 0.05) and none of the metabolite, immune, vagal, or clinical measures show the predicted directional differences between active‑ and rest‑phase dosing, the hypothesis is falsified. Conversely, a significant interaction with the predicted improvements only in the active‑phase condition supports the mechanistic claim that circadian timing gates microbiota‑brain communication.